Cosmos Health Inc. (COSM) - 8-K Summary
Business Context and Reporting Period
Cosmos Health Inc., a Nevada corporation trading on the Nasdaq Capital Market, filed this Current Report on Form 8-K on August 19, 2026. The filing announces financial results for the second fiscal quarter and the first six months ended June 30, 2026.
Key Financial Metrics
- Revenue: Q2 2026 revenue reached $19.0 million; H1 2026 revenue totaled $36.9 million.
- Profitability: Q2 Adjusted Gross Profit increased by 58%.
- Balance Sheet: Total liabilities decreased by 13%, while Stockholders' Equity increased by 12%.
- Cash Flow & Liquidity: Specific cash flow and liquidity figures are not provided in the filing text; details are contained in the attached press release (Exhibit 99.1).
- Capital Allocation: The Company has initiated a $5 million share repurchase program.
Material Changes vs. Prior Period
- Revenue Growth: Q2 revenue grew 29% year-over-year; H1 revenue grew 30% year-over-year.
- Margin Expansion: Adjusted Gross Profit for Q2 saw a significant 58% increase.
- Debt Reduction: The company successfully reduced total liabilities by 13%.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements regarding future results, expectations, and plans. Management cautions that actual results may differ materially due to risks and uncertainties beyond the Company's control. No specific quantitative guidance or outlook figures are provided in this 8-K text; investors are directed to the attached press release and the Annual Report on Form 10-K for the fiscal year ended December 31, 2025, for detailed risk factors.
Investor Verification Checklist
- Verify the specific Adjusted Gross Profit margin percentage and net income figures in the attached Exhibit 99.1 press release.
- Confirm the details of the $5 million share repurchase program, including authorization date and execution status.
- Review the breakdown of the 13% reduction in total liabilities to understand debt repayment versus operational changes.
- Examine the 10-K for the fiscal year ended December 31, 2025, for comprehensive risk factors referenced in the forward-looking statements.